NCT06274528
DORA and LP in Alzheimer's Disease Biomarkers
Recruiting · Phase 2 · University of Minnesota · registry updated 2026-07-13
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.
Inclusion
- Male or female.
- Any race or ethnicity.
- Participants must be age ≥ 65 years and able to sign informed consent.
- Global Clinical Dementia Rating (CDR) 0.
- Willing and able to undergo study procedures.
Exclusion
- History or reported symptoms suggestive of restless legs syndrome, narcolepsy, or parasomnia.
- STOP-Bang score \>6 for participants without PAP.
- Untreated sleep apnea AHI\>15
- Poorly treated sleep apnea due to noncompliance or an AHI ≥ 10.
- \- PAP compliance is defined as ≥ 4 hours per night \>70% of the nights.
- Plasma p-Tau217/np-Tau217% \<2.5